SEP 29, 2015 3:37 PM PDT

Switching On Immune Cells for Cancer Therapy

WRITTEN BY: Ilene Schneider
Killer T cells (green and red) surrounding a cancer cell.UC San Francisco scientists have developed a molecular “on switch” enabling tight control over the actions of T cells, immune system cells that have potential as cancer therapies. The innovation could sharply reduce severe, sometimes fatal side effects that have been a problem in advancing T cell-based treatments.

According to Wendell Lim, Ph.D., professor and chair of UCSF’s Department of Cellular and Molecular Pharmacology, and senior author of a new paper on the work, “Right now we put engineered T cells into patients and just hope for the best. This is the first of a series of ‘control knobs’ our lab is trying to create so doctors might have additional command over these cells once they’re inside the body.”

Scientists pursuing cell therapy have been refining cell-surface sensors called chimeric antigen receptors, or CARs. The CARs prompt T cells to zero in on particular proteins found primarily in tumors, where they launch cancer-killing immune responses.

CAR-equipped T cells can be successful in the treatment of chemotherapy-resistant leukemia, but they can cause side effects so severe that they may require monitoring in an Intensive Care Unit. Some patients have died after receiving CAR T cells or other engineered T cells.

Lim explained, “T cells are really powerful beasts, and they can be lethal when they’re activated. We’ve needed a remote control system that retains the power of these engineered T cells, but allows us to communicate specifically with them and manage them while they’re in the body.”

While some scientists have developed “suicide switches” that kill off CAR T cells if side effects become too dangerous, Lim thinks “that’s like shooting your own soldiers in the back. It requires completely aborting a complex and expensive treatment.”

As published in the September 24 issue of Science Express and reported in Bioscience Technology, the UCSF team took the opposite approach, creating a new type of CAR T cell that is “off” by default. In the same way as conventional CAR T cells, according to the article, “These newly developed T cells will navigate toward and interact with cancer cells, but will not launch any immune assault unless a specially designed drug has been administered. This controller drug forms a chemical bridge between components inside the CAR T cells, flipping the cells into an active, on status. When the drug is no longer present, the T cells revert to an off position.”
 
Lim concluded, “That we can engineer CAR T cells to have slightly different, quite powerful effects – even if for a subset of patients or for certain types of cancer – is really remarkable, and this is just the tip of the iceberg.”


 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 13, 2021
Cancer
New efforts to predict which patients will suffer from side effects from immunotherapy
APR 13, 2021
New efforts to predict which patients will suffer from side effects from immunotherapy
The findings from a study published in the Journal for ImmunoTherapy of Cancer give medical professionals a way to predi ...
MAY 19, 2021
Health & Medicine
Who Ages Better, Men or Women?
MAY 19, 2021
Who Ages Better, Men or Women?
The answer depends on what's considered more important – quantity or quality of years?  Previous studies ...
MAY 29, 2021
Cancer
New device detects skin cancer from tensile stiffness
MAY 29, 2021
New device detects skin cancer from tensile stiffness
A research team composed of scientists from City University of Hong Kong (CityU) has designed an automated non-invasive ...
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
Loading Comments...